rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Precision Optics Corporation, Inc.

POCI · Nasdaq

Health CareMedical DevicesNot moving yet

POCI stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 7.3% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$460K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
29 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$441KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Joseph Norman ForkeyChief Executive Officerbought1,388at $3.6030 Mar 2026filed 1 Apr 2026
Joseph TrautChief Operating Officerbought41,666at $3.6030 Mar 2026filed 1 Apr 2026
Wayne M. CollChief Financial Officerbought20,833at $3.6030 Mar 2026filed 1 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders29+3 on the quarter
New · exited7 · 4
Reported value$18.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NEEDHAM INVESTMENT MANAGEMENT LLCunchanged · filed 14 Aug 20261,670,550$8.5M00.0%
MYDA Advisors LLCreduced · filed 13 Aug 2026375,000$1.9M-25,000−6.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026325,751$1.7M+131,626+67.8%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 2026280,000$1.4M00.0%
WealthTrust Axiom LLCadded · filed 11 Aug 2026260,458$1.3M+6,350+2.5%
MORGAN STANLEYadded · filed 13 Aug 2026179,694$916K+35,900+25.0%
HighTower Advisors, LLCadded · filed 5 Aug 2026124,343$634K+27,778+28.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202666,137$337K+155+0.2%
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 202654,100$276K+54,100
ESSEX INVESTMENT MANAGEMENT CO LLCnew · filed 6 Aug 202646,630$238K+46,630
31 Mar 2023 – 30 Jun 2026
81828Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Wayne M. Coll Company insiderChief Financial Officer · last 30 Sep 20262 · 0
Joseph Norman Forkey Company insiderChief Executive Officer · last 21 Sep 20263 · 0
Joseph Traut Company insiderChief Operating Officer · last 21 Sep 20261 · 0
Peter Richard Thier Company insiderSenior VP - Sales & Marketing · last 18 Aug 20260 · 0
Andrew J. Miclot Company insiderDirector · last 12 Mar 20260 · 0
Buell Duncan Company insiderDirector · last 17 Nov 20250 · 0
Joseph P. Pellegrino Jr. Company insiderDirector · last 17 Nov 20250 · 0
Peter H. Woodward Company insiderDirector · last 17 Nov 20253 · 0
Mahesh Lawande Company insiderChief Operating Officer · last 19 Mar 20251 · 0
Peter V. Anania Company insiderDirector · last 20 Nov 20241 · 1
Richard B. Miles Company insiderDirector · last 18 Nov 20242 · 0
Daniel S. Habhegger Company insiderChief Financial Officer · last 1 Nov 20220 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 30 Jun 202617.2%
Operating profit marginFY 2026 · to 30 Jun 2026-11.1%
Free cash flow marginFY 2026 · to 30 Jun 2026-6.3%
Return on capital employedFY 2026 · to 30 Jun 2026-14.9%
Debt to equityFY 2026 · to 30 Jun 20260.09×
Research spendFY 2026 · to 30 Jun 20263.3%
Share count trendFY 2026 · to 20 Sep 20260.0%
Cash and equivalentsFY 2026 · to 30 Jun 2026$9.8M
Free cash flowFY 2026 · to 30 Jun 2026−$2.0M

Analyst forecasts

No analyst forecasts yet.